YauponYaupon CompanyYaupon Investigational DrugYaupon NewsYaupon Contact Us  
       
       
   
 
 
     
  Top News  
  RSS Feed  
     

MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone: 773-463-4211
beyer@sambrown.com 
 

 


June 5, 2012

CEPTARIS SECURES $10 MILLION IN SERIES D-1 FINANCING

MALVERN, PA (June 5, 2012) Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that it has raised $10 million through a Series D-1 private placement of preferred stock. This financing includes prior investors, Vivo Ventures, Palo Alto Investors, Burrill & Company, Aperture Venture Partners, Osage and BioAdvance, plus new investor, Third Point, LLC.

"We believe that our proprietary mechlorethamine gel will be an important new treatment option and this latest round of financing provides Ceptaris additional capital for ongoing activities," said Stephen Tullman, President and CEO at Ceptaris. "We appreciate the commitment of all of our investors and welcome Third Point, LLC, a valued investor familiar with the management team from an earlier investment in Ception Therapeutics."

Prior to the financing, Ceptaris received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The Company is working with the FDA to address the Agencys requests.

The funding will be used for operational expenses, including activities related to addressing the FDAs requests.

About Ceptaris Therapeutics

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris's investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer. Please visit www.ceptaris.com for more information.

# # #

Media Contact:
Mike Beyer, Sam Brown Inc.
beyer@sambrown.com
773-463-4211
 

 
   
     
 
   
   
   
   
         
print page